MENU
+Compare
ANVS
Stock ticker: NYSE
AS OF
Dec 3 closing price
Price
$4.65
Change
+$0.24 (+5.44%)
Capitalization
123.24M

ANVS Annovis Bio Forecast, Technical & Fundamental Analysis

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases... Show more

ANVS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for ANVS with price predictions
Nov 28, 2025

ANVS sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for ANVS moved above the 200-day moving average on November 19, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 11, 2025. You may want to consider a long position or call options on ANVS as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

ANVS moved above its 50-day moving average on November 12, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ANVS crossed bullishly above the 50-day moving average on November 17, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ANVS advanced for three days, in of 261 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 127 cases where ANVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANVS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ANVS broke above its upper Bollinger Band on November 25, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ANVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.363) is normal, around the industry mean (27.312). P/E Ratio (0.000) is within average values for comparable stocks, (52.442). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.886). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (321.020).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
ANVS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

ANVS is expected to report earnings to fall 7.49% to -34 cents per share on March 23

Annovis Bio ANVS Stock Earnings Reports
Q4'25
Est.
$-0.34
Q3'25
Missed
by $0.06
Q2'25
Beat
by $0.08
Q1'25
Beat
by $0.06
Q4'24
Missed
by $0.11
The last earnings report on November 12 showed earnings per share of -37 cents, missing the estimate of -31 cents. With 1.36M shares outstanding, the current market capitalization sits at 123.24M.
A.I. Advisor
published General Information

General Information

a developer of drugs for Alzheimer's and Parkinson's diseases and other neurodegenerative disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
101 Lindenwood Drive
Phone
+1 484 875-3192
Employees
6
Web
https://www.annovisbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BOUYF48.49N/A
N/A
Bouygues SA
RSGUF4.32N/A
N/A
Rogers Sugar Inc.
WKCMF77.00N/A
N/A
Wacker Chemie AG
TGAAF9.12N/A
N/A
Target Global Acquisition I Corp.
FTIDF0.18N/A
N/A
FTI Foodtech International, Inc.

ANVS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ANVS has been loosely correlated with ADXN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ANVS jumps, then ADXN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANVS
1D Price
Change %
ANVS100%
-1.80%
ADXN - ANVS
43%
Loosely correlated
-1.83%
ERAS - ANVS
37%
Loosely correlated
-3.50%
ALGS - ANVS
37%
Loosely correlated
+0.11%
RXRX - ANVS
37%
Loosely correlated
-0.69%
BDTX - ANVS
37%
Loosely correlated
-8.49%
More